The linked FDA record identifies QT Medical, Inc. as the applicant for a Traditional 510(k), K260250, received on January 27, 2026 and decided on September 29, 2026 with decision code SESE, meaning Substantially Equivalent. The submission sits under product code DPS, regulation 21 CFR 870.2340, device class 2, with the Cardiovascular review panel. The filing lists a Summary as the statement or summary type and records no third-party review. The applicant address in the filing is in Diamond Bar, California; that is a filing address, not a verified headquarters. [1][2][4]
Documented device and intended use
The cleared device names are the QCA 10 Electrocardiograph (QCARD-10) and QCA 10W Electrocardiograph (QCARD-10W). A device description summary in the filing describes a non-invasive, prescription 12-lead resting ECG for trained professionals, using 10 electrodes to capture and transmit cardiac signals to a Windows app in real time. The indications text describes the QCA 10/10W ECG System as a non-invasive prescription medical device intended for use by trained professionals. [1][4][5]
The filing lists K120865, RScirbe Electrocardiograph, product code DPS, as the predicate. The record states the subject devices are substantially equivalent to that predicate. Innolitics, which publishes the device page, also lists a Pediatric attribute among the device facts; the FDA record itself does not state that attribute. [4][5]
Submission scope and review path
K260250 followed the Traditional 510(k) route with no third-party review flag and a Cardiovascular advisory committee. The decision description is Substantially Equivalent, dated September 29, 2026, roughly eight months after the January 27, 2026 receipt date. The FDA database page for the same number shows a page update date of October 26, 2026. [1][2]
The supplied portfolio snapshot, retrieved November 20, 2026, contains one linked record, a 510(k), with one SESE decision in the full collection and the same single SESE decision in the smaller record sample. These counts describe the supplied filings at that retrieval time; they are not a measure of total company portfolio, sales or safety performance. [1]
Company statements and limits of the record
QT Medical's own About page, published by the company, describes it as a medical device company aiming to make hospital-grade 12-lead electrocardiograms accessible to everyone, with stated focus on telemedicine and home care. The same page lists milestones including NIH funding in 2013, a Taiwan branch established in 2015, and PCA 500 in 2018. Those are company-published statements, not FDA findings. [3]
The record does not establish ownership, a parent company, a brand hierarchy, customers, commercial availability, certifications or clinical performance for the QCA 10 or QCA 10W. No recall records appear in the supplied sample. The relationship between the company's PCA 500 milestone and the QCA 10/10W devices is not described in the public documents and remains unknown. [1][3]
